Results 101 to 110 of about 9,364 (186)

Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025. [PDF]

CPT Pharmacometrics Syst Pharmacol
Cordes H, Annaert P, Balazki P, Benamara S, Bonan RH, Butler A, Chenel M, Cui Y, Dallmann A, de Witte WEA, Demeester C, Feick D, Gattacceca F, Geci R, Gerebtzoff G, Gruber A, Guimarães M, Hamadeh A, Hanke N, Ibarra M, Ince I, Kanacher T, Kuepfer L, Mil F, Montaseri G, Nauwelaerts N, Proenca S, Schaller S, Schlender JF, Schneider ARP, Sjögren E, Solodenko J, Staab A, Vrenken P, Troisi C, Teutonico D.   +35 more
europepmc   +1 more source

A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy Adults. [PDF]

Adv Ther
Darwish M, Yamamoto A, Adegbenle Y, Tejwani R, Chen Y, Nunez-Disla R, Youakim JM, Pathak S.   +7 more
europepmc   +1 more source

Unraveling the complex role of intestinal microbiota in drug permeability: Insights from N-acetylcysteine. [PDF]

Asian J Pharm Sci
Tian C, He Z.
europepmc   +1 more source

Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation. [PDF]

Pharmaceut Med
Bartlett JA, Culver N, Santangelo M, Prpich A, Long E, Sagawa K, Shanker R, Xu H, Wilner K.   +8 more
europepmc   +1 more source

Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies. [PDF]

Ther Adv Respir Dis
Bednarczyk A, Aurivillius M, Jassal M, Shah M, Raphiou I, Petullo D, Xu J, Heijer M, Sychowicz K, Collison K, Silva C, Reddy J, Han D, Goldwater R, Gillen M, Patel M.   +15 more
europepmc   +1 more source

Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial. [PDF]

Support Care Cancer
Gasanin E, Bezzo R, Spinelli T, Seitz F.
europepmc   +1 more source

A comparative pharmacokinetic evaluation of two aqueous progesterone 25 mg injections in healthy postmenopausal women under fasting conditions: An open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study. [PDF]

Clin Pharmacol Drug Dev
Vyas N, Chakra A, Sarode P, Dharmadhikari S, Puppalwar G, Khandhedia C, Mane A, Goyani A, Khopade AJ.   +8 more
europepmc   +1 more source

Breaking barriers: how generic drugs democratize mental health. [PDF]

Front Pharmacol
Rosas-Sánchez GU, Mercado-Serna M, Fernández-Demeneghi R, Pérez-Vega MI, Soria-Fregozo C.   +4 more
europepmc   +1 more source

Clinical analysis of drug treatment trends for coronary heart disease in China. [PDF]

Front Med (Lausanne)
Li X, Lou J, Li X, Li S, Gu J, Zhang D, Luo Z, Cao J, Xie J.   +8 more
europepmc   +1 more source

A Single Dose, Randomized, Open-Label, Cross-Over Bioequivalence Study of Budesonide Pressurized Metered-Dose Inhaler in Healthy Chinese Subjects. [PDF]

Pharmacol Res Perspect
Huang K, Yin S, Huang W, Ding L, Qin W, Qian Z, Ding Y, Que L, Shi Y, Gao J, Zhao Y.   +10 more
europepmc   +1 more source